Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 16, 2015 - Issue 7
Submit an article Journal homepage
3,989
Views
31
CrossRef citations to date
0
Altmetric
Original Research

Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: a pooled analysis of two Phase III clinical studies

Takashi KadowakiThe University of Tokyo, Graduate School of Medicine, Department of Metabolic Disease, Tokyo, Japan
,
Fuyuhiko MarubayashiMitsubishi Tanabe Pharma Corp, Development Division, Clinical Research Department II, Tokyo, Japan
,
Shoko YokotaMitsubishi Tanabe Pharma Corp, Development Division, Data Science Department, Tokyo, Japan
,
Makoto KatohMitsubishi Tanabe Pharma Corp, Pharmacovigilance and Quality Assurance Division, Medical Affairs Department, Tokyo, Japan
&
Hiroaki IijimaMitsubishi Tanabe Pharma Corp, Pharmacovigilance and Quality Assurance Division, Medical Affairs Department, 3-16-89 Kashima, Yodogawa-ku, Osaka 532-8505, Japan+81 6 6300 3063; +81 6 6300 2655; [email protected]
Pages 971-981 | Published online: 10 Apr 2015

Bibliography

  • Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest 2007;117:24-32
  • Russell S. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction. Int J Clin Pharm 2013;35:159-72
  • Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705
  • Scheen AJ. A review of gliptins for 2014. Expert Opin Pharmacother 2015;16:43-62
  • Filippatos TD, Athyros VG, Elisaf MS, et al. The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors. Expert Opin Drug Metab Toxicol 2014;10:787-812
  • Goda M, Kadowaki T. Teneligliptin for the treatment of type 2 diabetes. Drugs Today (Barc) 2013;49:615-29
  • Morishita R, Nakagami H. Teneligliptin: expectations for its pleiotropic action. Expert Opin Pharmacother 2015;16:417-26
  • Nabeno M, Akahoshi F, Kishida H, et al. A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. Biochem Biophys Res Commun 2013;434:191-6
  • Eto T, Inoue S, Kadowaki T. Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2012;14:1040-6
  • Tsuchimochi W, Ueno H, Yamashita E, et al. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients. Endocr J 2015;62:13-20
  • Kadowaki T, Kondo K. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2013;15:810-18
  • Kadowaki T, Kondo K. Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig 2013;4:576-84
  • Kadowaki T, Kondo K. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension. Diabetes Obes Metab 2014;16:418-25
  • Kim YG, Hahn S, Oh TJ, et al. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 2013;56:696-708
  • Park H, Park C, Kim Y, Rascati KL. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis. Ann Pharmacother 2012;46:1453-69
  • Japan Diabetes Society. Evidence-based Practice Guideline for the Treatment for Diabetes in Japan. 2013. Available from: http://www.jds.or.jp/modules/en/index.php?content_id =44 [Last accessed 11 November 2014]
  • Konya H, Yano Y, Matsutani S, et al. Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients. Ther Clin Risk Manag 2014;10:547-58
  • Yabe D, Seino Y. Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: friend or foe? J Diabetes Investig 2014;5:475-7
  • Maeda H, Kubota A, Tanaka Y, et al. The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes. Diabetes Res Clin Pract 2012;95:e20-2
  • Nakamaru Y, Hayashi Y, Ikegawa R, et al. Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans. Xenobiotica 2014;44:242-53
  • Halabi A, Maatouk H, Siegler KE, et al. Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment. Clin Pharmacol Drug Dev 2014;3:290-6
  • Halabi A, Maatouk H, Siegler KE, et al. Pharmacokinetics of teneligliptin in subjects with renal impairment. Clin Pharmacol Drug Dev 2013;2:246-54
  • Otsuki H, Kosaka T, Nakamura K, et al. Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes. Int Urol Nephrol 2014;46:427-32
  • Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26
  • White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-35
  • Tanaka S, Suzuki K, Aoki C, et al. Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy. Diabetes Technol Ther 2014;16:1-6
  • Kinoshita S, Kondo K. Evaluation of pharmacokinetic and pharmacodynamic interactions of canagliflozin and teneligliptin in Japanese healthy male volunteers. Expert Opin Drug Metab Toxicol 2015;11:7-14

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.